Back to Search
Start Over
Switching of biologics in psoriasis: Reasons and results.
- Source :
-
The Journal of dermatology [J Dermatol] 2017 Sep; Vol. 44 (9), pp. 1015-1019. Date of Electronic Publication: 2017 May 10. - Publication Year :
- 2017
-
Abstract
- Efficacy and safety profiles of biologics have been established for moderate to severe psoriasis. However, inefficacy or adverse events sometimes require changing the treatment to other biologics. Here, we examine the effectiveness of this strategy. We retrospectively investigated cases requiring switching biologics. We enrolled 275 psoriatic patients treated with biologics between January 2010 and December 2014 in our hospital. Of these, 51 required a switch to another biologic. First-line therapies were infliximab (IFX, n = 26), adalimumab (ADA, n = 18) and ustekinumab (UST, n = 7), and second-line therapies were IFX (n = 5), ADA (n = 21) and UST (n = 25). Reasons for switching were inefficacy (n = 38), adverse events (n = 11) and others (n = 2). The details were primary failure (n = 15), secondary failure (n = 23) and infusion reactions (n = 8). In 49 patients who switched biologics due to inefficacy and adverse events, the mean Psoriasis Area and Severity Index (PASI) score at week 16 was 4.3 for first-line therapies and 2.9 for second-line therapies (P < 0.05). Switching to a second biologic therapy to address the first's inefficacy or adverse events often results in significant improvement in moderate to severe psoriasis.<br /> (© 2017 Japanese Dermatological Association.)
- Subjects :
- Adalimumab therapeutic use
Adult
Aged
Female
Humans
Infliximab therapeutic use
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Failure
Treatment Outcome
Ustekinumab therapeutic use
Biological Products therapeutic use
Dermatologic Agents therapeutic use
Drug Substitution adverse effects
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1346-8138
- Volume :
- 44
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- The Journal of dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 28488283
- Full Text :
- https://doi.org/10.1111/1346-8138.13860